The Global Alliance for TB Drug Development (TB Alliance) and AstraZeneca have announced a research collaboration agreement to accelerate the discovery, development and clinical use of drugs against tuberculosis (TB).

The collaboration will specifically target drug-resistant strains of the disease, which account for at least one in five cases, according to World Health Organization data.

Under the agreement, the TB Alliance and AstraZeneca will develop promising TB drug discovery projects into a joint portfolio.

The initial set of projects contributed by the TB Alliance result from ongoing collaboration with researchers at the University of Pennsylvania, Rutgers University and the New York Medical College.

AstraZeneca’s projects will come from its TB research centre in Bangalore, India, where a joint portfolio will be resourced by a core group of scientists, with expertise and funding provided by both organisations.

Financial terms were not disclosed.